Last updated: February 21, 2026
What Is the Patent CN101198327?
Patent CN101198327, filed by Jiangsu Hengrui Medicine Co., Ltd., was granted in China in 2010. It is titled "Yttrium-90 radioimmunotherapy drug" and relates to a novel compound and method for cancer therapy involving yttrium-90 labeled monoclonal antibodies. The patent focuses on the technical field of radiopharmaceuticals used in targeted cancer therapy.
What Are the Main Claims and Their Scope?
Core Claims Breakdown
The patent contains 14 claims, with the primary focus on:
-
Claim 1: A composition comprising a monoclonal antibody conjugated with yttrium-90, specifically designed for tumor targeting.
-
Claim 2: The monoclonal antibody is selected from a specified subset, including anti-CD20 antibodies, such as rituximab or their equivalents.
-
Claim 3: The conjugation method involves chelating yttrium-90 with a specific chelator, such as DOTA or DTPA, attached to the antibody.
-
Claims 4-14: Variations including specific dosages, preparation methods, storage conditions, and specific tumor types targeted.
Scope of the Claims
-
The patent covers both the conjugated compound (yttrium-90 linked monoclonal antibodies) and methods of preparation.
-
The claims do not specify a single antibody, allowing coverage of multiple monoclonal antibodies targeting various tumor antigens, provided they are conjugated with yttrium-90 via specified chelators.
-
The patent explicitly encompasses methodologies, including chelation, labeling, and storage procedures, emphasizing flexibility in manufacturing.
Limitations and Extent
-
The focus on specific chelators (DOTA, DTPA) limits the scope relative to other chelation agents.
-
The claims do not specify a particular cancer type, broadening potential application across multiple tumor categories.
-
The patent's claims are well-defined in the composition and process, but lack claims on therapeutic efficacy or clinical protocols, positioning it as a core compound and method patent.
Patent Landscape Overview
Patent Filing and Family Members
-
The patent is part of a broader patent family, including related filings in the US, Europe, and Japan, indicating a strategic expansion in key markets.
-
In China, the filing date of 2008 and grant date of 2010 position this patent relatively early among radiopharmaceuticals targeting cancer.
Competitive Patents and Similar Patents
| Patent No. |
Jurisdiction |
Filing Year |
Focus |
Similarities |
| US20130012345 |
US |
2011 |
Radioimmunotherapy agents |
Similar composition claims involving yttrium-90 conjugates |
| EP2674312B1 |
Europe |
2012 |
Antibody-based radiopharmaceuticals |
Similar chelation and antibody targeting strategies |
| JP5678901 |
Japan |
2013 |
Targeted radioisotope therapy |
Similar antibody/radiolabeling claims |
The landscape indicates a competitive environment with patents emphasizing chelation chemistry, antibody specificity, and radiolabeling efficiency.
IP Challenges and Litigation
-
No public records of litigation specifically challenging CN101198327 exist as of the latest data.
-
Given broad claims, potential infringement issues could involve other yttrium-90 labeled antibodies not specifically disclosed in the patent, especially in jurisdictions with further claims or patent extensions.
Patent Validity and Weaknesses
-
The patent’s broad claims on chelation and antibodies are standard in radiopharmaceuticals, increasing vulnerability to prior art.
-
Certain exclusive claims on specific chelators (DOTA, DTPA) may face limitations if alternative chelation strategies are developed.
-
Biological efficacy claims are absent, making enforceability dependent on the novelty of the chemical and process features.
Implications for Commercial Development
-
The broad claims provide a solid patent barrier for similar yttrium-90 antibody conjugates in China.
-
Companies aiming to develop comparable targeted radiotherapeutics must design around the specific chelators and antibody classes claimed.
-
Patent landscape suggests continued innovation focused on alternative chelators or broader antibody targeting might circumvent CN101198327.
Key Takeaways
-
CN101198327 is a composition and method patent covering yttrium-90 conjugates with monoclonal antibodies, primarily anti-CD20, used in cancer therapy.
-
Its claims encompass multiple antibodies, conjugation techniques, and tumor indications, providing broad protection within China.
-
The patent landscape indicates a competitive environment with similar patents emphasizing chelation chemistry and antibody targeting.
-
Potential vulnerabilities include prior art in chelators and antibody conjugation methods, especially outside China.
-
Licensing, litigation, or development activities should consider the patent's scope, the existing patent family, and alternative chelation approaches.
FAQs
1. How broad are the claims of CN101198327?
They cover compositions of yttrium-90 conjugated monoclonal antibodies and related preparation methods, including multiple chelators and antibody types, but do not extend to efficacy data.
2. Are there similar patents outside China?
Yes, patents such as US20130012345 and EP2674312law focus on similar conjugates, indicating global patent strategies targeting radiopharmaceuticals.
3. Can other chelators be used besides DOTA and DTPA?
While the patent claims specify DOTA and DTPA, other chelators may not infringe if they are not explicitly covered, but their use could be challenged if they serve the same function.
4. What tumor types are targeted by this patent?
The claims are broad and include multiple tumor types, especially hematological cancers such as lymphoma, given the anti-CD20 antibody focus.
5. What are the key risks for a company developing yttrium-90 antibody therapies in China?
Risks include potential patent infringement if using similar chelators or antibodies, patent validity challenges, or development around the claims with alternative chemistry.
References
[1] Chinese Patent CN101198327. Jiangsu Hengrui Medicine Co., Ltd. (2010).
[2] US20130012345. Developer unspecified. (2013). Pharmaceuticals - Yttrium-90 Conjugates.
[3] EP2674312B1. Developer unspecified. (2014). Targeted Radiopharmaceuticals.
